DK0812208T3 - Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer - Google Patents

Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer

Info

Publication number
DK0812208T3
DK0812208T3 DK96909604T DK96909604T DK0812208T3 DK 0812208 T3 DK0812208 T3 DK 0812208T3 DK 96909604 T DK96909604 T DK 96909604T DK 96909604 T DK96909604 T DK 96909604T DK 0812208 T3 DK0812208 T3 DK 0812208T3
Authority
DK
Denmark
Prior art keywords
pct
controlled release
pharmaceutical compositions
soluble receptors
ligand
Prior art date
Application number
DK96909604T
Other languages
Danish (da)
English (en)
Inventor
David Wallach
Josef Kost
Rom Eliaz
Original Assignee
Yeda Res & Dev
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ben Gurion filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0812208T3 publication Critical patent/DK0812208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96909604T 1995-03-01 1996-03-01 Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer DK0812208T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors
PCT/US1996/003121 WO1996026738A1 (fr) 1995-03-01 1996-03-01 Compositions pharmaceutiques destinees a la liberation regulee de recepteurs solubles

Publications (1)

Publication Number Publication Date
DK0812208T3 true DK0812208T3 (da) 2009-03-16

Family

ID=11067150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909604T DK0812208T3 (da) 1995-03-01 1996-03-01 Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer

Country Status (19)

Country Link
US (1) US6083534A (fr)
EP (1) EP0812208B1 (fr)
JP (1) JP4447052B2 (fr)
KR (1) KR100417650B1 (fr)
CN (1) CN1133464C (fr)
AT (1) ATE415941T1 (fr)
AU (1) AU692384B2 (fr)
BR (1) BR9607289A (fr)
CA (1) CA2213560C (fr)
DE (1) DE69637768D1 (fr)
DK (1) DK0812208T3 (fr)
EA (1) EA199700206A1 (fr)
ES (1) ES2318849T3 (fr)
IL (1) IL112834A (fr)
MX (1) MX9706626A (fr)
NO (2) NO323003B1 (fr)
PT (1) PT812208E (fr)
UA (1) UA44761C2 (fr)
WO (1) WO1996026738A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1206275B1 (fr) * 1998-11-05 2007-09-05 Omeros Corporation Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
EP1216037A2 (fr) * 1999-09-21 2002-06-26 Emory University Procedes et compositions pour le traitement de troubles lies aux plaquettes au moyen d'agents inhibiteurs de trajet de mpl
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ES2601143T3 (es) * 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
CN102772357B (zh) 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
CA2588908C (fr) * 2004-11-29 2014-09-23 Yeda Research And Development Co. Ltd Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
CN101500606B (zh) * 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递系统
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
CA2721927C (fr) 2008-04-21 2014-01-28 Otonomy, Inc. Preparations auriculaires de traitement de maladies et etats otiques
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CR20160147A (es) 2011-03-25 2016-08-03 Amgen Inc Formulaciones de anticuerpos
US20150125471A1 (en) * 2012-05-03 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
WO2014046631A1 (fr) 2012-09-19 2014-03-27 Tezcaner Aysen Systèmes d'administration contrôlée de médicaments anti-tnfα
WO2015119653A1 (fr) 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Échafaudage d'administration de médicament ou endoprothèse vasculaire avec un revêtement à base de novolimus et de lactide tel que le novolimus présente une quantité minimale de liaison au revêtement
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US10611850B2 (en) 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
EP3328898B8 (fr) 2015-07-28 2024-04-10 6452728 Canada Corp. Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
JP5938762B1 (ja) 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
KR20200108873A (ko) 2018-01-09 2020-09-21 오토노미, 인코포레이티드 성장 인자 귀 제제
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019226519A1 (fr) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
WO2019222856A1 (fr) 2018-05-24 2019-11-28 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993015722A1 (fr) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
WO1994006476A1 (fr) * 1992-09-15 1994-03-31 Immunex Corporation Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf
EP0646000A4 (fr) * 1992-11-16 1997-05-02 Univ Mercer Compositions comprenant des anticorps de neutralisation microencapsules.

Also Published As

Publication number Publication date
NO20056197L (no) 1997-11-03
EP0812208A1 (fr) 1997-12-17
UA44761C2 (uk) 2002-03-15
AU692384B2 (en) 1998-06-04
CN1133464C (zh) 2004-01-07
EP0812208A4 (fr) 2004-06-30
US6083534A (en) 2000-07-04
IL112834A (en) 2000-12-06
PT812208E (pt) 2009-02-06
JP4447052B2 (ja) 2010-04-07
NO323003B1 (no) 2006-12-18
CN1182369A (zh) 1998-05-20
DE69637768D1 (de) 2009-01-15
WO1996026738A1 (fr) 1996-09-06
MX9706626A (es) 1998-02-28
KR19980702640A (ko) 1998-08-05
JPH11501306A (ja) 1999-02-02
NO973812L (no) 1997-11-03
ATE415941T1 (de) 2008-12-15
AU5303996A (en) 1996-09-18
ES2318849T3 (es) 2009-05-01
KR100417650B1 (ko) 2004-05-20
NO328034B1 (no) 2009-11-16
EA199700206A1 (ru) 1998-02-26
CA2213560A1 (fr) 1996-09-06
IL112834A0 (en) 1995-06-29
NO973812D0 (no) 1997-08-19
BR9607289A (pt) 1998-06-23
CA2213560C (fr) 2010-08-24
EP0812208B1 (fr) 2008-12-03

Similar Documents

Publication Publication Date Title
DK0812208T3 (da) Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer
US4968317B1 (en) Surgical materials and devices
ATE222505T1 (de) Flüssige polymerzusammensetzung und verfahren zu ihrer verwendung
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
DK0772441T3 (da) Progesteronantagonist og gestagen til behandling af endometriose og leiomyomata
ES2104157T3 (es) Emplasto con sustancias activas, para sustancias activas de bajo punto de fusion y/o volatiles.
FI913410A (fi) Kontinuerligt frigoerande farmaceutiska kompositioner.
IL116083A0 (en) Liquid pharmaceutical compositions containing ondansetron and their use
DE69934582D1 (de) Delavirdin tablettenformulierung
DE69228997D1 (de) Menschliche il-3-varianten
PT999843E (pt) Composicoes farmaceuticas contendo vitamina d e calcio, sua preparacao e uso terapeutico
ATE171869T1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20032906B (en) Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure